Progentos Therapeutics

About Progentos Therapeutics

Progentos Therapeutics is a company focused on developing regenerative medicines for chronic diseases, with a particular emphasis on a new approach to treating multiple sclerosis (MS) by stimulating the body's natural repair mechanisms to regenerate myelin and repair damage caused by MS.

Products & Services

Small-Molecule Therapeutics for MS:Novel, first-in-class small-molecule therapeutics designed to activate oligodendrocyte progenitor cells to regenerate oligodendrocytes and remyelinate neurons in multiple sclerosis patients, potentially preventing further decline or restoring function.

Regenerative Medicine for MS:A regenerative medicine aimed at improving the quality of life for MS patients by targeting remyelination through a novel target and new chemical entities identified in pre-clinical studies.

Specialties

Regenerative Medicine Multiple Sclerosis Treatment Remyelination Therapeutics Small-Molecule Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 65000000 MR: - FA: $65 Million FAN: 65000000	D: 2024-05-20 FD: 2024-05-20	5 investors

Series A Latest

2024-05-20

$65.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Marc-Oliver Turgeon

Senior Associate

M

Marc-Olivier

Senior Associate

A

Aleks Radovic-Moreno

Partner at Longwood Fund

B

Bob Langer

A

Andrew Miller

Biopharmaceutical Executive

D

Dan Janney

Managing Partner of Alta Partners

View 10 more team members with Pro

Unlock Full Team Directory

Recent News